Company Legal Name
Latest Valuation
Founded Year
Headquarter
Conceivable Life Sciences develops automated IVF laboratory systems that integrate artificial intelligence and robotics to streamline fertility treatment processes for clinics and laboratories. The New York City-based company addresses critical challenges in reproductive medicine by automating traditionally manual, time-intensive procedures that require high precision and consistency. Their technology platform aims to reduce human error, increase laboratory efficiency, and potentially improve patient outcomes in fertility treatments. Operating in the growing fertility technology sector, Conceivable Life Sciences targets the increasing demand for assisted reproductive technologies as more individuals and couples seek fertility services globally. The company continues advancing its AI-driven automation solutions for widespread clinical adoption.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
